13F Data
13F filer · CIK 2054410

ACORN CAPITAL ADVISORS, LLC

NEW YORK, NY · filing since Q4 2024 · last filing Aug 14, 2026
Reported value
$366.5M
+$14.6M vs prior
Positions
20
New / sold out
1 / 3
Added / reduced
5 / 3
Turnover
5.9%
buys $21.1M · sells $119.1M
Top-10 weight
90.2%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
AddedKARYOPHARM THERAPEUTICS INC+1,230,287+427.4%+$12.0M
AddedJADE BIOSCEINCES INC+200,000+25.4%+$4.4M
AddedAURA BIOSCIENCES INC+333,333+56.0%+$2.4M
NewEUGENE THERAPEUTICS+1,271,257–+$2.2M
AddedCG ONCOLOGY INC+999+0.1%+$71.0K
AddedJASPER THERAPEUTICS+26,667+1.9%+$11.2K

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outTERNS PHARMACEUTICALS INC-1,746,264-100.0%$-92.1M
ReducedBIOATLA INC-5,298,219-98.0%$-21.9M
Sold outCARDIF ONCOLOGY INC-1,762,084-100.0%$-2.9M
ReducedQ32 BIO INC.-98,881-31.4%$-1.3M
Sold outX4 PHARMACEUTICALS INC-234,039-100.0%$-966.6K
ReducedBICARA THERAPEUTICS-1-0.0%$-30

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2024: $185.8MQ1 2025: $149.9MQ2 2025: $152.9MQ3 2025: $197.0MQ4 2025: $295.1MQ1 2026: $351.8MQ2 2026: $366.5M
Q4 2024Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1CG ONCOLOGY INCCOM1,131,500$80.4M21.94%
2UROGEN PHARMA LTDCOM1,673,420$61.6M16.80%
3TREVI THERAPEUTICS INCCOM2,144,844$40.0M10.92%
4CANDEL THERAPEUTICS INCCOM3,497,948$36.0M9.83%
5PUMA BIOTECHNOLOGY INCCOM4,131,299$33.5M9.14%
6JADE BIOSCEINCES INCCOM NEW986,760$21.9M5.98%
7BICARA THERAPEUTICSCOM643,381$19.1M5.21%
8KARYOPHARM THERAPEUTICS INCCOMMON STOCK1,518,113$14.8M4.05%
9ONKURE THERAPEUTICS INCCLASS A COM2,839,674$12.9M3.53%
10HELUS PHARMA INC.COM STK1,540,266$10.2M2.78%
10 more rows. Subscribe for $29/month to see every row, download the data and use the API.